GlaxoSmithKline to acquire biotechnology company 35Pharma for $950 million
Show original
Gelonghui, February 25th | GlaxoSmithKline announced that it has agreed to acquire Canadian biotechnology company 35Pharma for $950 million in cash. This marks the second major deal reached by the company's new CEO, Luke Miels, to accelerate new drug development. 35Pharma's experimental pulmonary arterial hypertension drug HS235 will strengthen GlaxoSmithKline's future respiratory drug pipeline.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
PoolX: Earn new token airdrops
Lock your assets and earn 10%+ APR
Lock now!
You may also like
GasFree is now available on several major wallets on the TRON network
Chaincatcher•2026/02/26 09:29
Venus and Fluid jointly launch unified liquidity product Venus Flux
ForesightNews•2026/02/26 09:18
BlockSec: Ploutus suffers $390,000 loss due to oracle misconfiguration, attacker borrows 187 ETH with just 8 USDC
ForesightNews•2026/02/26 09:01
Trending news
MoreCrypto prices
More
Bitcoin
BTC
$68,253.42
+3.56%
Ethereum
ETH
$2,066.83
+6.44%
Tether USDt
USDT
$0.9999
-0.03%
XRP
XRP
$1.44
+3.72%
BNB
BNB
$624.79
+2.74%
USDC
USDC
$0.9999
-0.06%
Solana
SOL
$87.34
+4.77%
TRON
TRX
$0.2865
+0.31%
Dogecoin
DOGE
$0.09877
+4.35%
Cardano
ADA
$0.2900
+5.98%
How to buy BTC
Bitget lists BTC – Buy or sell BTC quickly on Bitget!
Trade now
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now